Seminars in Colon & Rectal Surgery
Volume 17, Issue 2 , Pages 50-54 , June 2006

Medical Management of Surgical Inflammatory Bowel Disease? Current Concepts and Future Possibilities

  • Shehzad Sheikh, MD
    • ,
  • Scott Plevy, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Scott Plevy, MD, Associate Professor of Medicine, Inflammatory Bowel Disease Center, University of North Carolina School of Medicine, CB 7032, 7341C MBRB, Chapel Hill, NC 27599.

References 

  1. Fefferman DS , Farrell RJ . Immunogenicity of biological agents in inflammatory bowel disease . Inflamm Bowel Dis . 2005;11:497–503
  2. Papachristou GI , Plevy S . Novel biologics in inflammatory bowel disease . Gastroenterol Clin North Am . 2004;33:251–269
  3. Rutgeerts P , Van Assche G , Vermeire S . Optimizing anti-TNF treatment in inflammatory bowel disease . Gastroenterology . 2004;126:1593–1610
  4. Sandborn WJ . New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease . Rev Gastroenterol Disord . 2005;5:10–18
  5. Sandborn WJ . Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease . Curr Gastroenterol Rep . 2003;5:501–505
  6. Sandborn WJ , Faubion WA . Biologics in inflammatory bowel disease: how much progress have we made? . Gut . 2004;53:1366–1373
  7. Van Assche G , Vermeire S , Rutgeerts P . Medical treatment of inflammatory bowel diseases . Curr Opin Gastroenterol . 2005;21:443–447
  8. Schwartz DA , Loftus EV , Tremaine WJ , et al.   The natural history of fistulizing Crohn’s disease in Olmsted County, MN . Gastroenterology . 2002;122:875–880
  9. Farmer RG , Hawk WA , Turnbull RB . Clinical patterns in Crohn’s disease: a statistical study of 615 cases . Gastroenterology . 1975;68:627–635
  10. Rankin GB , Watts HD , Melnyk CS , et al.   National Cooperative Crohn’s Disease Study: extraintestinal manifestations and perianal complications . Gastroenterology . 1979;77:914–920
  11. Steinberg DM , Cook WT , Alexander-Williams J . Abscess and fistulae in Crohn’s disease . Gut . 1973;14:865–869
  12. Hellers G , Bergstrand O , Ewerth S , et al.   Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease . Gut . 1980;21:525–527
  13. American Gastroenterological Association medical position statement (perianal Crohn’s disease) . Gastroenterology . 2003;125:1503–1507
  14. Bell SJ , Williams AB , Wiesel P , et al.   The clinical course of fistulating Crohn’s disease . Aliment Pharmacol Ther . 2003;17:1145–1151
  15. Scott HJ , Northover JM . Evaluation of surgery for perianal Crohn’s fistulas . Dis Colon Rectum . 1996;39:1039–1043
  16. Topstad DR , Panaccione R , Heine JA , et al.   Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience . Dis Colon Rectum . 2003;46:577–583
  17. Braegger CP , Nicholls S , Murch SH , et al.   Tumour necrosis factor alpha in stool as a marker of intestinal inflammation . Lancet . 1992;339:89–91
  18. Brynskov J , Nielsen OH , Ahnfelt-Ronne I , et al.   Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn’s disease and ulcerative colitis): a review . Dig Dis . 1994;12:290–304
  19. Van Deventer SJ . Tumour necrosis factor and Crohn’s disease . Gut . 1997;40:443–448
  20. Hanauer SB , Feagan BG , Lichtenstein GR , et al.   Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial . Lancet . 2002;359:1541–1549
  21. Present DH , Rutgeerts P , Targan S , et al.   Infliximab for the treatment of fistulas in patients with Crohn’s disease . N Engl J Med . 1999;340:1398–1405
  22. Sands BE , Anderson FH , Bernstein CN , et al.   Infliximab maintenance therapy for fistulizing Crohn’s disease . N Engl J Med . 2004;350:876–885
  23. Targan SR , Hanauer SB , van Deventer SJ , et al.  Crohn’s Disease cA2 Study Group   A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease . N Engl J Med . 1997;337:1029–1035
  24. Huang CS , Becker JM , Farraye FA . Successful closure of ileal pouch-vaginal fistulas with infliximab . Gastroenterology . 2003;125:631–633
  25. Sands BE , Blank MA , Patel K , et al.   Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study . Clin Gastroenterol Hepatol . 2004;2:912–920
  26. Van Assche G , Vanbeckevoort D , Bielen D , et al.   Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease . Am J Gastroenterol . 2003;98:332–339
  27. Rasul I , Wilson SR , MacRae H , et al.   Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn’s disease . Am J Gastroenterol . 2004;99:82–88
  28. Schwartz DA , White CM , Wise PE , et al.   Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn’s perianal fistulas . Inflamm Bowel Dis . 2005;11:727–732
  29. Lichtenstein GR , Yan S , Bala M , et al.   Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease . Gastroenterology . 2005;128:862–869
  30. Lichtenstein GR , Yan S , Bala M , et al.   Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries . Am J Gastroenterol . 2004;99:91–96
  31. Wong JB , Loftus EV , Sandborn WJ , et al.   Estimating cost-effectiveness of maintenance infliximab for chronic active Crohn’s disease from ACCENT I . Gut . 2003;52:A54; (abstract)
  32. Regueiro M , Mardini H . Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement . Inflamm Bowel Dis . 2003;9:98–103
  33. Talbot C , Sagar PM , Johnston MJ , et al.   Infliximab in the surgical management of complex fistulating anal Crohn’s disease . Colorectal Dis . 2005;7:164–168
  34. van der Hagen SJ , Baeten CG , Soeters PB , et al.   Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn’s disease: a preliminary report . Dis Colon Rectum . 2005;48:758–767
  35. Baert F , Noman M , Vermeire S , et al.   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease . N Engl J Med . 2003;348:601–608
  36. Rutgeerts P , Feagan BG , Lichtenstein GR , et al.   Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease . Gastroenterology . 2004;126:402–413
  37. Di Sabatino A , Ciccocioppo R , Benazzato L , et al.   Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn’s disease patients . Aliment Pharmacol Ther . 2004;19:1019–1024
  38. Holtmann MH , Neurath MF . Anti-TNF strategies in stenosing and fistulizing Crohn’s disease . Int J Colorectal Dis . 2005;20:1–8
  39. Knapp AB , Mirsky FJ , Dillon EH , et al.   Successful infliximab therapy for a duodenal stricture caused by Crohn’s disease . Inflamm Bowel Dis . 2005;11:1123–1125
  40. Sorrentino D , Avellini C , Beltrami CA , et al.   Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn’s disease . Int J Colorectal Dis . 2006;21:276–281
  41. Colombel JF , Loftus EV , Tremaine WJ , et al.   Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy . Am J Gastroenterol . 2004;99:878–883
  42. Marchal L , D’Haens G , Van Assche G , et al.   The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study . Aliment Pharmacol Ther . 2004;19:749–754
  43. Cima RR , Pemberton JH . Medical and surgical management of chronic ulcerative colitis . Arch Surg . 2005;140:300–310
  44. Cima RR , Pemberton JH . Surgical indications and procedures in ulcerative colitis . Curr Treat Options Gastroenterol . 2004;7:181–190
  45. Farouk R , Pemberton JH , Wolff BG , et al.   Functional outcomes after ileal pouch-anal anastomosis for chronic ulcerative colitis . Ann Surg . 2000;231:919–926
  46. Meagher AP , Farouk R , Dozois RR , et al.   J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients . Br J Surg . 1998;85:800–803
  47. Olsen KO , Joelsson M , Laurberg S , et al.   Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis . Br J Surg . 1999;86:493–495
  48. Penna C , Dozois R , Tremaine W , et al.   Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis . Gut . 1996;38:234–239
  49. Svaninger G , Nordgren S , Oresland T , et al.   Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch . Scand J Gastroenterol . 1993;28:695–700
  50. Lichtiger S , Present DH , Kornbluth A , et al.   Cyclosporine in severe ulcerative colitis refractory to steroid therapy . N Engl J Med . 1994;330:1841–1845
  51. Van Assche G , D’Haens G , Noman M , et al.   Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis . Gastroenterology . 2003;125:1025–1031
  52. Sandborn WJ . Severe ulcerative colitis . Curr Treat Options Gastroenterol . 1999;2:113–118
  53. Campbell S , Travis S , Jewell D . Ciclosporin use in acute ulcerative colitis: a long-term experience . Eur J Gastroenterol Hepatol . 2005;17:79–84
  54. Cohen RD , Stein R , Hanauer SB . Intravenous cyclosporin in ulcerative colitis: a five-year experience . Am J Gastroenterol . 1999;94:1587–1592
  55. Rowe FA , Walker JH , Karp LC , et al.   Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis . Am J Gastroenterol . 2000;95:2000–2008
  56. Rutgeerts P , Sandborn WJ , Feagan BG , et al.   Infliximab for induction and maintenance therapy for ulcerative colitis . N Engl J Med . 2005;353:2462–2476
  57. Jarnerot G , Hertervig E , Friis-Liby I , et al.   Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study . Gastroenterology . 2005;128:1805–1811
  58. Regueiro M , Curtis-Radin J , Plevy S . Infliximab for hospitalized patients with severe ulcerative colitis . J Clin Gastroenterol . 2006;40:476–481
  59. Plevy SSB , van Assche G , Regueiro M , et al.   A humanized anti-CD3 monoclonal antibody, Visilizumab, for treatment of severe steroid-refractory ulcerative colitis: results of a Phase I study . Gastroenterology . 2004;126:A75
  60. Targan SR , Salzberg BA , Mayer L , et al.   A phase I-II study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvements in ulcerative colitis patients refractory to treatment with IV steroids . Gastroenterology . 2005;128:A75

PII: S1043-1489(06)00061-3

doi: 10.1053/j.scrs.2006.06.007

Seminars in Colon & Rectal Surgery
Volume 17, Issue 2 , Pages 50-54 , June 2006

Article Tools